ÖAW Österreichische Akademie der Wissenschaften, Institute of Molecular Biotechnologiy
The IMBA - Institute of Molecular Biotechnology is a research organisation founded as a joint initiative of the Austrian Academy of Sciences* and the pharmaceutical company Boehringer Ingelheim. IMBA uses model organisms and cutting-edge functional genomics to investigate fundamental molecular processes and their contribution to disease. In interdisciplinary research groups, IMBA pursues an integrative approach that combines functional screening, cellular RNAi, stem cell and imaging technologies with the knowledge to rapidly generate mouse disease models to examine the role of genes in physiology and pathogenesis. Numerous co-operations with leading academic and industrial partners are an integral part of IMBA’s strategy and commitment to deliver outstanding results from its basic research and to translate these discoveries into future human medicine. Potential fields of application include major disease areas such as inflammation, autoimmune disorders, cardiovascular and neurodegenerative diseases, and cancer.